AGENUS INC Accumulated Other Comprehensive Income
AGENUS INC (AGEN) had Accumulated Other Comprehensive Income of -$450.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-07
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$450.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$437.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$439.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.56M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2026-06-30 | -$450.00K 10-Q · filed 2026-08-07 | |
| 2026-03-31 | -$437.00K 10-Q · filed 2026-05-11 | |
| 2025-12-31 | -$439.00K 10-Q · filed 2026-08-07 | |
| 2025-09-30 | -$1.56M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | -$1.50M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | -$1.47M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | -$1.40M 10-K · filed 2026-03-16 | |
| 2024-09-30 | -$1.35M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$1.00M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | -$1.07M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | -$955.00K 10-K · filed 2025-03-17 | |
| 2023-09-30 | -$1.03M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | -$717.00K 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $917.00K 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $915.00K 10-K · filed 2024-03-14 | |
| 2022-09-30 | $644.00K 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $2.15M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $970.00K 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $1.49M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $177.00K 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $260.00K 10-Q · filed 2021-08-09 | |
| 2021-03-31 | -$1.00M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $2.77M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $1.23M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $369.00K 10-Q · filed 2020-08-10 | |
| 2020-03-31 | -$97.00K 10-Q · filed 2020-05-11 | |
| 2019-12-31 | -$1.32M 10-K · filed 2021-03-16 | |
| 2019-09-30 | -$1.28M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | -$1.08M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | -$2.22M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | -$1.54M 10-K · filed 2020-03-16 | -$1.54M 10-K · filed 2019-03-18 |
| 2018-09-30 | -$1.62M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | -$1.58M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | -$2.71M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | -$2.17M 10-K · filed 2019-03-18 | |
| 2017-09-30 | -$2.06M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | -$2.29M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | -$1.66M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | -$1.53M 10-K · filed 2018-03-16 | |
| 2016-09-30 | -$1.56M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | -$1.66M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | -$1.51M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | -$2.05M 10-K · filed 2017-03-16 | |
| 2015-09-30 | -$1.33M 10-Q · filed 2015-11-04 | |
| 2015-06-30 | -$658.40K 10-Q · filed 2015-08-03 | |
| 2015-03-31 | -$1.21M 10-Q · filed 2015-05-01 | |
| 2014-12-31 | -$1.97M 10-K · filed 2016-03-15 | |
| 2014-09-30 | -$1.16M 10-Q · filed 2014-10-31 | |
| 2014-06-30 | $135.64K 10-Q · filed 2014-08-01 | |
| 2013-12-31 | $0.00 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |